SCHEMBL13956768

SCHEMBL13956768

Cc1cc(=O)n(Cc2ccccc2)c(C(N)C(C)C)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 4/20 0.46
▸ HPGD P15428 4/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PSMD14 O00487 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ CASR P41180 1/20 0.43
▸ ATM Q13315 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ HSD17B10 Q99714 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ TYMS P04818 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4365755 0.79 TLR7 (0.46) TLR7HPGDMEN1KMT2AKDM4E
SCHEMBL4367588 0.79 TLR7 (0.46) TLR7HPGDMEN1KMT2AKDM4E
SCHEMBL13956775 0.78 TLR7 (0.39) TLR7HPGDMEN1KMT2AKDM4E
SCHEMBL14408874 0.75 KDM4E (0.47) TLR7HPGDMEN1KMT2AKDM4E
SCHEMBL12391809 0.74 TSHR (0.52) MEN1KMT2ATSHRHTTMAPT
SCHEMBL1038904 0.74 TSHR (0.52) MEN1KMT2ATSHRHTTMAPT
SCHEMBL6017319 0.74 EGLN1 (0.39) TLR7HPGDMEN1KMT2AKDM4E
SCHEMBL3235521 0.74 MEN1 (0.61) MEN1KMT2ATSHRALDH1A1LMNA
SCHEMBL3494747 0.74 MEN1 (0.61) MEN1KMT2ATSHRALDH1A1LMNA
SCHEMBL13963463 0.74 HPGD (0.43) TLR7HPGDMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482343-B2 Compounds, methods and compositions CYTOKINETICS, INC. (US) 2009-01-27 — — US disclosed
US-7482343-B2 Compounds, methods and compositions CYTOKINETICS, INC. (US) 2009-01-27 — — US disclosed
US-20070135432-A1 Compounds, methods and compositions CYTOKINETICS, INC. 2007-06-14 — — US disclosed
US-20070135432-A1 Compounds, methods and compositions CYTOKINETICS, INC. 2007-06-14 — — US disclosed
US-7166595-B2 Compounds, methods and compositions CYTOKINETICS, INC. (US) 2007-01-23 — — US disclosed
US-7166595-B2 Compounds, methods and compositions CYTOKINETICS, INC. (US) 2007-01-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135432-A1 Compounds, methods and compositions ALPP, PCNA, MKI67 TLR7 4822/4885HPGD 887/4885MEN1 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback